Inclusion Criteria
- Women, age 18 or older, enrolled in the Palopegteriparatide Pregnancy Registry
- Lactating females who are receiving therapeutic doses of palopegteriparatide as part of usual care, have chosen to breastfeed their infant(s), and have been taking palopegteriparatide for at least 14 days prior to sample collection
Exclusion Criteria
- Presence of any medical condition that, in the opinion of the investigator, may impair the ability to breastfeed during this study, including but not limited to mastitis and nipple malformation
For additional study information and for inclusion/exclusion criteria: Healthcare providers may visit ClinicalTrials.gov (NCT07264634).
Ascendis Pharma does not recommend or endorse using its medications in a way that conflicts with FDA-approved labeling.
